Table 3.
Univariate analysis for metastasis-free survival after salvage radiotherapy
| Variable | Hazard ratio (HR) | 95% CI | p-value |
|---|---|---|---|
|
Age, yrs Cont |
0.96 | 0.89–1.03 | 0.24 |
|
First post- prostatectomy PSA Cont |
1.07 | 1.03–1.12 | 0.002 |
|
PreRT PSA Cont |
1.07 | 0.98–1.16 | 0.053 |
| Fractionation schedule | |||
| 66 Gy/33x | 1.0 | ||
| 52.5 Gy/20x | 1.28 | 0.47–3.47 | 0.62 |
| ADT during RT | |||
| No | 1.0 | ||
| Yes | 7.83 | 1.0–59.3 | 0.05 |
|
Final pathology Grade Group Gleason score |
overall p = 0.001 | ||
| 1 | 1.0 | ||
| 2 | 0.0 | 0.01–14.9 | 0.945 |
| 3 | 0.32 | 0.06–1.56 | 0.16 |
| 4 | 0.14 | 0.01–1.52 | 0.11 |
| 5 | 1.06 | 0.2–5.57 | 0.95 |
| pT stage | overall p = 0.002 | ||
| T1–T2a | 1.0 | ||
| T2b–T2c | 55.08 | 0.002–64.8 | 0.96 |
| T3–T4 | 49.9 | 0.004–56.1 | 0.95 |
| SVI | |||
| No | 1.0 | ||
| Yes | 3.48 | 1.26–9.60 | 0.02 |
| Positive surgical margins | |||
| No | 1.0 | ||
| Yes | 2.86 | 1.03–7.97 | 0.04 |
| ECE | |||
| No | 1.0 | ||
| Yes | 7.02 | 1.96–25.07 | 0.003 |
yrs years, cont continuous, PSA prostate-specific antigen, ADT androgen deprivation therapy, RT radiotherapy, SVI seminal vesicle invasion, ECE extracapsular extension